Alex H. Chang

Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 93 publications

Correction: CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

Correction: CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

Journal: Leukemia

Published: August 10, 2026

Impact of TP53 mutations on survival outcomes in the CAR-T era of large B-cell lymphoma.

Impact of TP53 mutations on survival outcomes in the CAR-T era of large B-cell lymphoma.

Journal: Frontiers in immunology

Published: March 05, 2026

Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).

Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 27, 2026

Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies.

Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies.

Journal: Experimental hematology & oncology

Published: February 06, 2026

Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease.

Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease.

Journal: Blood

Published: February 03, 2026

CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

Journal: Leukemia

Published: January 28, 2026

Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T-Cell Infusion: A Case Report With Mechanistic Insight.

Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T-Cell Infusion: A Case Report With Mechanistic Insight.

Journal: Hematological oncology

Published: January 14, 2026

CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.

CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.

Journal: The New England journal of medicine

Published: January 14, 2026

Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR-T Treated T-cell Lymphoid Malignancies.

Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR-T Treated T-cell Lymphoid Malignancies.

Journal: Blood cancer discovery

Published: January 05, 2026

Efficacy of BCMA CAR-T cell therapy and subsequent strategies in refractory and relapsed plasma cell leukemia: a retrospective cohort study.

Efficacy of BCMA CAR-T cell therapy and subsequent strategies in refractory and relapsed plasma cell leukemia: a retrospective cohort study.

Journal: Frontiers in immunology

Published: November 28, 2025

Immune microenvironment and its influence on CAR-T treatment outcomes in B-NHL.

Immune microenvironment and its influence on CAR-T treatment outcomes in B-NHL.

Journal: Discover oncology

Published: November 25, 2025

CD19/BCMA-Targeted Chimeric Antigen Receptor-T Cell Therapy for Anti-HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical Study.

CD19/BCMA-Targeted Chimeric Antigen Receptor-T Cell Therapy for Anti-HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical Study.

Journal: HLA

Published: November 23, 2025

Showing 1-12 of 93

Last Updated: 09/26/2026